Quotient Wealth Partners LLC Sells 1,711 Shares of Pfizer Inc. (NYSE:PFE)

Quotient Wealth Partners LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 16.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,556 shares of the biopharmaceutical company’s stock after selling 1,711 shares during the period. Quotient Wealth Partners LLC’s holdings in Pfizer were worth $227,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Ritholtz Wealth Management boosted its stake in shares of Pfizer by 26.3% during the third quarter. Ritholtz Wealth Management now owns 55,267 shares of the biopharmaceutical company’s stock valued at $1,599,000 after purchasing an additional 11,519 shares during the period. Retirement Planning Group LLC bought a new stake in Pfizer during the 3rd quarter valued at about $354,000. Exchange Traded Concepts LLC boosted its position in Pfizer by 117.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock valued at $2,002,000 after buying an additional 37,293 shares during the period. Willis Investment Counsel grew its stake in Pfizer by 0.5% in the 3rd quarter. Willis Investment Counsel now owns 1,297,206 shares of the biopharmaceutical company’s stock worth $37,541,000 after acquiring an additional 6,966 shares in the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its position in shares of Pfizer by 11.4% during the third quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 2,286,226 shares of the biopharmaceutical company’s stock worth $66,163,000 after acquiring an additional 233,900 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $25.87 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $146.58 billion, a PE ratio of 18.34, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a fifty day moving average price of $26.28 and a 200-day moving average price of $27.72.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the business posted $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.65%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Analyst Ratings Changes

Several brokerages recently issued reports on PFE. Guggenheim reissued a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.